Research-use-only educational overview. This is not medical advice and not a recommendation to use, buy, or take any compound. When people search for the “best peptides for longevity and anti-aging,” they usually mean something more specific than the phrase suggests: which peptides are most studied and most discussed in the context of aging, and what does the evidence actually show? That is the question this page answers. It is worth being blunt up front: “most studied” is not the same as “proven to work,” and neither is the same as “right for you.” Much of the excitement around longevity peptides comes from cell cultures and animal experiments that have never been replicated in rigorous human trials. Sources indexed in PubMed and ClinicalTrials.gov are linked throughout so you can read the primary evidence yourself.
Below we look at five compounds frequently named in longevity discussions, rank the honesty of the evidence behind each, and link each to its research dosage reference. None of this should be read as an endorsement.
Comparison at a glance
| Peptide | What it’s studied for (longevity/anti-aging) | Evidence tier | Key caveat |
|---|---|---|---|
| Epithalon (AEDG) | Telomerase activation, melatonin/circadian regulation, antioxidant effects | Preclinical (cell/animal) + older, weak human data | No modern controlled human longevity trials |
| MOTS-c | Mitochondrial metabolism, insulin sensitivity, exercise/aging biology | Preclinical only + human observational correlation | No published human efficacy trials |
| NAD+ (and precursors) | Restoring the age-related decline in cellular NAD+ | Early human clinical (RCTs, mostly on oral precursors) | Trials raise NAD+ but rarely change hard outcomes |
| Thymalin | Thymic/immune restoration in older adults | Older human observational + animal data | Methodologically weak; not independently replicated |
| SS-31 (elamipretide) | Protecting mitochondrial function and cardiolipin | Preclinical + human disease trials | Largest phase-3 trial missed its primary endpoints |
The five peptides, and what research shows
Epithalon (Epitalon / AEDG)
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on Epithalamin, a pineal-gland extract. In laboratory and animal models it has been reported to activate telomerase, influence melatonin synthesis, and produce antioxidant and geroprotective effects, though a 2025 review notes the mechanisms remain incompletely characterized (Araj et al., 2025). The strongest longevity-specific data are old and preclinical: the parent extract Epithalamin increased mean lifespan in fruit flies, mice, and rats by roughly 11–31% (Anisimov et al., 1998). Human longevity claims trace mainly to older Russian observational work, not modern randomized trials, so the honest tier here is “promising in animals, unproven in people.” See the Epithalon research dosage reference for context on how it is handled in a lab setting.
MOTS-c
MOTS-c is a mitochondrial-derived peptide that acts through the AMPK pathway and whose circulating levels appear to decline with age. In preclinical models it improves glucose metabolism in skeletal muscle and is studied as a regulator of metabolic stress and aging biology (Zheng et al., 2023; Wan et al., 2023). The critical caveat: reviewers themselves note that no effective clinical application has been established and human efficacy trials are lacking. Evidence here is preclinical plus observational human correlation only. Details on the compound are outlined in the MOTS-c research dosage reference.
NAD+ (and its precursors)
NAD+ is a coenzyme central to energy metabolism whose levels fall with age, which is why raising it is one of the most actively tested ideas in the aging field (Campisi et al., 2019). This is the best-studied entry here in humans, but almost all of that data comes from oral precursors rather than injectable NAD+ itself. In a randomized placebo-controlled trial, nicotinamide riboside raised blood NAD+ about 2.6-fold in older adults with mild cognitive impairment and was well tolerated, yet it did not improve cognition (Orr et al., 2023). A separate NMN trial found dose-dependent NAD+ increases that correlated with modest gains in a 6-minute walk test (Kuerec et al., 2024). Bottom line: trials reliably raise the biomarker, but rarely move hard aging outcomes. The NAD+ research dosage reference covers the injectable form.
Thymalin
Thymalin is a thymic peptide preparation studied on the premise that restoring age-related decline in immune (thymic) function could support healthier aging. The most-cited human claim comes from a long-term Russian study in which Thymalin, alone or combined with Epithalamin, was associated with reduced mortality and lower rates of age-related disease in people over 60 (Khavinson & Morozov, 2002). Those results are striking on paper but come from older, methodologically limited work that has not been independently replicated in modern controlled trials, so they should be read with real caution. The Thymalin research dosage reference provides background on the compound.
SS-31 (elamipretide)
SS-31, also called elamipretide, is a mitochondria-targeting peptide that binds cardiolipin on the inner mitochondrial membrane and, in preclinical models, restores mitochondrial bioenergetics relevant to age-related decline (Szeto, 2014). It is the most clinically advanced peptide here, but the human record is sobering: the pivotal phase-3 MMPOWER-3 trial in primary mitochondrial myopathy found that elamipretide did not improve the 6-minute walk test or fatigue versus placebo, though it was well tolerated (Karaa et al., 2023). That is a disease trial rather than a longevity trial, but it is the strongest efficacy signal available, and it was negative on its primary endpoints. See the SS-31 research dosage reference for more.
What the evidence actually supports
Ranked honestly by strength of human evidence, NAD+ (through oral precursors) sits at the top of this list simply because it has multiple randomized controlled trials, though even those mostly demonstrate a biomarker change rather than a longevity benefit. SS-31 has the most advanced clinical program, but its largest trial failed its primary endpoints. Epithalon and MOTS-c rest largely on animal and cell work, with human longevity claims that are either very old (Epithalon) or essentially absent (MOTS-c). Thymalin’s dramatic mortality figures come from dated, unreplicated research. In short: none of these five has robust, modern, controlled human evidence of extending human lifespan or reversing aging. The compounds with genuinely strong human efficacy data in the broader “metabolic aging” conversation, such as GLP-1 receptor agonists for weight and metabolic outcomes, are not on this list precisely because they are a different class with a different, much larger evidence base.
Important limitations
- Research-use-only. Every compound discussed here is presented for educational and research context. None is described as a treatment, and nothing here tells you to use, buy, or take any of them.
- Not approved for longevity or anti-aging. None of these peptides is an approved anti-aging therapy. Elamipretide has been studied in specific mitochondrial diseases; the others are largely investigational or sold only as research chemicals.
- Individual results and safety are unknown. Long-term safety data in healthy people are minimal to nonexistent for most of these, and animal or biomarker results do not reliably predict human outcomes.
- Not medical advice. Consult a qualified healthcare professional before making any health decision. If you are exploring the numbers behind published research protocols, a peptide dosage calculator can help you understand reconstitution math in a research context only.
FAQ
Which peptide has the strongest human evidence for aging?
Of these five, NAD+ (via oral precursors such as NR and NMN) has the most human randomized-trial data. But even those trials mainly show that NAD+ levels rise, not that aging is slowed or reversed. Human longevity outcomes remain unproven for the whole group.
Do any of these peptides actually extend human lifespan?
No peptide here has been shown to extend human lifespan in controlled trials. Lifespan-extension data exist for the pineal extract Epithalamin in flies, mice, and rats (Anisimov et al., 1998), but animal findings frequently fail to translate to people.
Is “most studied” the same as “best”?
No. “Most studied” or “most discussed” reflects research and marketing attention, not proven benefit or safety. A compound can be widely talked about and still lack the controlled human evidence needed to call it effective, which is exactly the situation for most peptides in longevity conversations.
